Nonacosanol

Other Names

(10S)-nonacosan-10-ol(R)-10-Nonacosanol(S)-10-Nonacosanol1-Nonacosanol10-Nonacosanol10-Nonacosanol, (10S)-15-NonacosanolCelidoniolGinnoln-nonacosanolnonacosan-1-olnonacosan-10-olnonacosan-15-olnonacosyl alcohol

Synopsis

Nonacosanol (1-Nonacosanol): A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Names and Basic Chemistry

Nonacosanol, formally designated 1-nonacosanol, is a straight-chain aliphatic 29-carbon primary fatty alcohol. It belongs to the broader class of very-long-chain primary aliphatic alcohols (VLCAls), which are defined by carbon backbone lengths ranging from 20 to 36 carbons. Its molecular formula is C₂₉H₆₀O, with PubChem CID 243696. The compound's CAS Registry Number is 6624-76-6. As a primary alcohol, its hydroxyl (–OH) group is located at the terminal (C-1) carbon of the straight saturated chain. The molecule is entirely saturated — containing no carbon–carbon double bonds — and is therefore classified as a saturated fatty alcohol.

Within the policosanol literature, nonacosanol carries the shorthand designation C29 or C29OH. Policosanol exists in nature as a white crystal or powder that contains a mixture of alcohol esters with carbon chains ranging from 22 to 34 in length. These alcohols include docosanol (C-22), tetracosanol (C-24), hexacosanol (C-26), octacosanol (C-28), nonacosanol (C-29), triacontanol (C-30), dotriacontanol (C-32), and tetratriacontanol (C-34), which are only stable in nature as a mixture (policosanol).

In standardized Cuban policosanol (Raydel®), 1-nonacosanol (C₂₉H₅₉OH) is specified at a concentration of 1.0–20.0 mg/g of the total mixture. This quantitative specification places nonacosanol firmly among the minor components of policosanol. Policosanol is a group of long-chain alcohols with a carbon length of 20–36 atoms, of which docosanol (C22), tetracosanol (C24), hexacosanol (C26), octacosanol (C28), and triacontanol (C30) are the major components, and heptacosanol (C27), nonacosanol (C29), dotriacontanol (C32), and tetratriacontanol (C34) are the minor components.

1.2 Position within the Policosanol Complex

Policosanol is the generic term for a mixture of long-chain alcohols extracted from plant waxes. The major components of the policosanol mixture are octacosanol (66%), triacontanol (12%), and hexacosanol (7%). Nonacosanol, as a C29 alcohol, occupies an intermediate position in the homologous series — flanked on either side by the dominant C28 (octacosanol) and C30 (triacontanol) alcohols. Because nonacosanol is not commercially isolated as a standalone supplement, the peer-reviewed literature addresses it almost exclusively in the context of policosanol mixtures. Any biological data attributed specifically to nonacosanol must therefore be interpreted with the understanding that it has been studied as a component of a multi-alcohol mixture rather than as a pure isolated substance.

Policosanols (PCs) are a mixture of long-chain aliphatic primary alcohols (C₂₀OH–C₃₆OH). PCs are present in very low amounts in raw waxy material since they are bonded to fatty acids to form esters. For this reason, it is necessary to perform either a saponification or a trans-esterification procedure to free them from their ester form.

2. Natural Sources and Botanical Distribution

2.1 Primary Plant Sources

1-Nonacosanol is a straight-chain aliphatic 29-carbon primary fatty alcohol found in a variety of plants including sisal (Agave sisalana). More broadly, nonacosanol is distributed across the wide range of plants that produce policosanol-containing waxes. Policosanol was originally derived from sugarcane, but the chemicals can also be isolated from beeswax, cereal grains, grasses, leaves, fruits, nuts, and seeds of many foods.

Policosanol was initially isolated from sugarcane wax by Cuban researchers and developed by Cuban Dalmer Laboratories. Other sources of policosanol include beeswax, wheat, sorghum, maize, rice, broccoli, spinach, alfalfa, and other cereal grains. Major natural sources of policosanols are sugarcane and rice bran, but also beeswax and wheat germ.

HPLC-ELSD analysis of the purified mixture from hemp wax revealed C₂₆OH and C₂₈OH as the main compounds, confirming that Cannabis sativa (hemp) is an additional, though not commercially prominent, botanical source of policosanol alcohols. Policosanol is widely distributed naturally and can be isolated and purified from rice bran, sugarcane, apples, grapes, etc.

2.2 Comparative Quantitative Concentrations by Source

The concentration of total policosanol — and by extension nonacosanol as a minor constituent — varies substantially by source and extraction method. The precipitate formed during the cold storage of commercially hexane-extracted wheat germ oil (WGO) contained the highest total policosanol (628 mg/kg) among the wheat extracts and milling products examined. The total policosanol contents of wheat straw (164 mg/kg) and sugar cane peel (270 mg/kg) were of the same order of magnitude. The total policosanol contents of brown beeswax were about 20 and 45 times higher than those of the WGO-solids and sugar cane peel, respectively.

These sources may have different relative proportions of policosanol components, meaning that the proportion of nonacosanol within a given policosanol preparation will depend significantly on the botanical origin of the material.

2.3 Extraction and Purification

Policosanol is derived through hydrolysis of wax esters and isolation of the alcohol constituent. Because the alcohols are bound to fatty acids as wax esters in the natural plant matrix, liberation requires saponification or trans-esterification. Starting from hemp wax material, policosanols were obtained by microwave-assisted trans-esterification and hydrolysis, followed by preparative liquid chromatography under normal-phase conditions. These mixtures are analysed by gas chromatography coupled with mass spectrometry (GC-MS). Nanoemulsion technology has also been explored to improve oral bioavailability. In one study, policosanol was extracted from rice bran wax, its composition was determined by GC-MS, and a nanoemulsion was made with a nanosize particle distribution below 100 nm (92.56–94.52 nm), with optimum charge distribution.

3. Historical and Traditional Use

3.1 Origins of Policosanol Research and Use

There is no documented evidence of nonacosanol being isolated or used as a standalone therapeutic agent in traditional medicine systems prior to the modern era. The alcohol exists exclusively in the ethnobotanical and historical record as an undifferentiated component of plant waxes that were used in various preparations. The modern concept of policosanol — which includes nonacosanol as a defined constituent — arose from 20th-century industrial and pharmaceutical research rather than from classical herbalism.

Policosanol was a name originally given to a unique extract of Cuban sugarcane (Saccharum officinarum) derived from the plant's waxy fraction. In 1964, the Cuban Institute of Research on Sugar Cane Derivatives sought to identify high-value bioactive sugarcane derivatives. The first product with such potential was policosanol, eventually sold in 40 countries as a patented agent for lowering cholesterol.

Policosanol has been used in Cuba since 1991 to treat high cholesterol. The first policosanol supplements were produced by Dalmer Laboratories in Cuba; studies conducted and published by that group found that policosanol is safe and effective as a lipid-lowering agent. The Cuban product became the reference standard for all subsequent clinical research, and the specific ratio of constituent alcohols — including the defined quantity of nonacosanol — was a key element of what Cuban researchers termed "genuine policosanol."

3.2 Use of Wax-Containing Plants in Traditional Settings

Sisal (Agave sisalana), one of the documented botanical sources of 1-nonacosanol, has an uncertain native origin but is thought to have originated in the Mexican state of Chiapas, where it was historically used by the Aztecs and Maya for a crude fabric. However, the use of sisal in Mesoamerican traditions was as a fiber crop, not as a medicinal preparation intended to deliver long-chain alcohols. No primary source documents the deliberate consumption of sisal or other nonacosanol-containing plant waxes for health purposes in pre-modern cultures.

Beeswax — among the richest natural sources of policosanol per gram — has been consumed incidentally in traditional honey harvesting across numerous cultures, but again without specific attribution to its long-chain alcohol constituents. The identification, isolation, and characterization of individual alcohols such as nonacosanol is a product of 20th-century analytical chemistry.

4. Key Constituents, Chemical Context, and Mechanisms of Action

4.1 Nonacosanol within the Policosanol Alcohol Series

Policosanol is the term for a mixture of very long-chain aliphatic alcohols (24–34 carbon length). They are naturally found in a variety of plant germs, (plant and insect) waxes, seeds, leaves, and grasses. Within this mixture, although octacosanol is the major component of Cuban policosanol, exhibiting some of the main pharmacological effects, the activity of the mixture seems to be superior in some experimental models. This suggests the minor components — including nonacosanol — may contribute to the overall biological activity, though the precise independent contribution of the C29 alcohol remains unresolved.

Octacosanol has been shown to have anti-inflammatory effects, while triacontanol can prevent oxidative stress, induce anti-inflammatory responses, and inhibit lipid peroxidation. On the other hand, hexacosanol has been demonstrated to have an ability to reduce hepatic and plasma cholesterol through the AMPK pathway and suppression of SREBP2 in HepG2 and C57BL/6J mice. The published literature does not attribute a uniquely characterized mechanism to nonacosanol specifically, distinct from the mixture's general activities.

4.2 AMPK Pathway and Cholesterol Metabolism

The most thoroughly investigated molecular mechanism for policosanol — and by implication for its components including nonacosanol — involves the AMP-activated protein kinase (AMPK) pathway. The proposed mechanisms of action of policosanol include binding to the β-subunit of adenosine 5′-monophosphate (AMP)-activated protein kinase and activating the AMPK pathway, which suppresses the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCS2) reductase enzyme, resulting in increased receptor-mediated uptake of LDL in the liver via increasing hepatic LDL receptors.

Similarly, AMPK activation leads to the inhibition of cholesteryl ester transfer protein (CETP), thus preventing the binding of HDL and LDL to CETP, with resultant increase in LDL catabolism and a decrease in the metabolism of triglycerides. Inhibition of CETP activity may also lead to anti-inflammatory and anti-aging effects resulting in tissue regeneration and cellular replication.

Studies demonstrate that policosanol promotes the phosphorylation of AMP-kinase and HMG-CoA reductase in hepatoma cells and in mouse liver after intragastric administration, providing a possible means by which policosanol might lower blood cholesterol levels. Treatment of hepatoma cells with policosanol produced a 2.5-fold or greater increase in the phosphorylation of AMP-kinase and HMG-CoA reductase, and increased the phosphorylation of Ca⁺⁺/calmodulin-dependent kinase kinase (CaMKK), an upstream AMP-kinase kinase.

However, the translational relevance of this mechanism at human doses is questioned. Although policosanol increases the phosphorylation of HMG-CoA reductase in mouse liver after intragastric administration, the ability of therapeutically recommended doses of policosanol to decrease blood cholesterol levels by this pathway remains in doubt. The doses used in preclinical studies, ranging from 10 to 100 mg/kg body weight, are considerably higher than those used in clinical studies, where the typical dose is between 5 to 80 mg per day. Assuming that the typical patient weighs 70 kg, a minimal 10 mg/kg dose would require a 35-fold higher dose than that typically used.

Additional mechanistic evidence from animal studies shows that policosanol supplementation stimulated an increase in fecal cholesterol and bile acid contents and deactivated HMG-CoA reductase by AMPK phosphorylation during high-fat and high-cholesterol-containing diet-induced development of hypercholesterolemia.

4.3 CETP Inhibition and HDL Functionality

Beyond the AMPK/HMG-CoA axis, policosanol has been studied for its effects on HDL quality and function. Besides the substantial effect of policosanol in inhibiting LDL oxidation, the elevation of HDL-cholesterol levels and the functionality enhancement of the HDL-associated antioxidant enzyme paraoxonase (PON)-1 have been documented. In a 2019 study, policosanol reconstituted with high-density lipoproteins (rHDL) showed distinct inhibition of glycation with similar extent in the presence of fructose, and showed strong antioxidant activity against cupric ion-mediated oxidation of LDL, and inhibition of oxidized-LDL uptake into macrophages.

4.4 Platelet Aggregation

The potential benefit for intermittent claudication is thought to be due to policosanol's ability to prevent platelets in the blood from sticking together and its potential anti-inflammatory activity. Policosanols have demonstrated inhibitory action on HMG-CoA reductase and on bile acid absorption, in addition to an activating effect on AMPK (increase of fatty acid β-oxidation).

4.5 Anti-inflammatory and Antioxidant Activity

In vitro assays on hemp-derived policosanols indicated an inhibition of intracellular reactive oxygen species (ROS) production, a reduction of nuclear factor kappa B (NF-κB) activation, and of the activity of the neutrophil elastase. Immunoblotting assays allowed researchers to hypothesize the mechanism of action of the compounds of interest, given the higher levels of MAPK-activated protein kinase 2 (MK2) and heme oxygenase-1 (HO-1) protein expression in policosanol-pretreated HaCaT cells.

4.6 Neuroprotective Mechanisms

Policosanol may suppress 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which induces the phosphorylation of c-Jun-N-terminal kinase (JNK) that has been implicated in Parkinsonism. In C. elegans models of Parkinson's disease, treatment with insect wax-derived policosanol reduced the aggregation of alpha-synuclein and 6-OHDA-induced neurodegeneration. It also extended the lifespan of the worms, though low doses were more protective than high doses.

4.7 Bioavailability

The bioavailability of policosanol is less than 10% when taken orally (the only route of administration), but tends to be improved either by nanoemulsification or by esterification with oleic acid. The absorption of policosanol was significantly higher in rats treated with policosanol esterified with oleic acid compared to those given nonesterified policosanol. In blood plasma, over 95% of policosanol was present as esterified alcohol, while 5% or less was detected as nonesterified policosanol.

5. Scientific Evidence by Area of Use

All scientific evidence referenced below pertains to policosanol as a mixture that includes nonacosanol as a minor constituent (typically 1.0–20.0 mg/g). No published clinical trials have specifically isolated nonacosanol for independent human study. All evidence, therefore, reflects the mixture's effects and must be interpreted accordingly.

5.1 Cardiovascular Health: Lipid Profile Modification

5.1.1 Early Cuban Clinical Research

The Cuban research group that holds the patent on sugarcane-derived policosanol published approximately eighty double-blind studies on its product. Several thousand people with elevated cholesterol levels were enrolled in clinical trials ranging in length from six weeks to twelve months. In virtually every one of these trials, policosanol proved both more effective than placebo and just as effective as statin drugs.

A representative early meta-analysis drawing primarily from Cuban data found: At doses of 10 to 20 mg per day, policosanol lowers total cholesterol by 17% to 21% and LDL cholesterol by 21% to 29%, and raises HDL cholesterol by 8% to 15%. In one double-blind, placebo-controlled Cuban trial of 56 patients with primary hypercholesterolemia: after adhering to a cholesterol-lowering diet for 6 weeks, patients were randomized to receive placebo or policosanol 5 mg once daily in the evening for 8 weeks. Total cholesterol and LDL cholesterol decreased significantly, by an average of 13.1% and 17.7%, respectively. No significant changes were observed for triglycerides, VLDL cholesterol, or HDL cholesterol.

Another Cuban randomized, double-blind study compared policosanol 20 mg/day vs. 40 mg/day: policosanol 20 mg/day lowered triglycerides by 12.7%, while they were lowered by 15.6% at a dose of 40 mg/day. Based on the mean values of LDL-cholesterol levels at study completion, the mean percent reductions from baseline were 27.4% and 28.1% for the 20 and 40 mg/day groups, respectively. Thus, the effects of both policosanol doses on the main efficacy variable were practically identical.

According to the Cuban data, policosanol can lower total cholesterol, lower LDL-cholesterol, and raise HDL-cholesterol.

5.1.2 Independent and Non-Cuban Clinical Research

In science, it is necessary to have independent confirmation of results before a treatment can be considered proven to work. The first truly independent trials of policosanol as a treatment for high cholesterol began to appear in 2006.

The largest independent trial, a randomized controlled trial by Berthold et al. (2006) conducted in Germany, enrolled 143 hypercholesterolemic subjects assigned to 10, 20, 40, or 80 mg of policosanol daily, or placebo. This trial showed that the administration of policosanols in hypercholesterolemic patients does not statistically improve the levels of total cholesterol, triglycerides, HDL-C, and LDL-C. This trial included 143 subjects divided into five groups each treated with 10, 20, 40, 80 mg of policosanols or placebo.

A North American randomized, placebo-controlled trial tested 20 mg/day of sugarcane-derived policosanol in participants with mild hypercholesterolemia. Researchers conducted a randomized, placebo-controlled trial to evaluate whether a 20-mg dose of sugar cane-derived policosanol could lower cholesterol in healthy participants with mild hypercholesterolemia who maintained a typical American diet, recruiting healthy male and female volunteers aged ≥18 years from the Charlotte, NC metropolitan area between January and June 2005. A notable study testing authentic Cuban sugarcane policosanol in people with high cholesterol found no significant difference between the supplement and placebo for total cholesterol, LDL, HDL, or triglycerides.

Cholesterol-lowering effects previously attributed to policosanol have not been validated by more recent trials. Later trials published from 2006 to 2009 in the United States, Italy, Germany, Netherlands, Canada, and South Africa found no effect on blood lipid profiles at dosages of 10 to 80 mg daily over 4 to 12 weeks.

A review of the literature identified a clear geographic clustering of positive results: a review paper entitled "Policosanols as Nutraceuticals: Fact or Fiction" showed that the predominant research on the lipid-lowering effects of policosanol at the time of publication was from a single research group of Dalmer Laboratories in La Habana, Cuba, and consequently highlighted the need for other independent and external experiments to confirm the effects. Guo and coworkers showed that policosanol does not affect lipid parameters in 16 healthy volunteers from China; however, the source and characteristic of policosanol used in this randomized trial was not mentioned.

In recent years, several clinical studies have suggested a reducing action of this nutraceutical on lipid profile, but the results are often non-significant.

A more recent (2023) randomized, placebo-controlled, double-blind trial in healthy Japanese subjects using Cuban policosanol (Raydel®, 20 mg/day for 12 weeks) reported that after 12 weeks of consumption, the policosanol group showed significantly lower blood pressure, glycated hemoglobin (HbA1c), and blood urea nitrogen (BUN) levels. This study used the specific eight-component Cuban formulation that includes 1-nonacosanol within its defined compositional specification.

Evidence strength (lipid-lowering): The overall evidence base is mixed and contested. Positive results are concentrated in Cuban industry-affiliated research. Multiple independent RCTs across multiple countries have failed to replicate the lipid-lowering effects. The evidence cannot currently be characterized as consistently supportive of clinically meaningful lipid reduction.

5.2 Blood Pressure

The most noteworthy effect of policosanol was the reported ability to alleviate metabolic disorders including dyslipidemia and hypertension. The Japanese RCT noted above reported blood pressure reduction at 20 mg/day over 12 weeks. In a human study, policosanol supplementation raised serum HDL-C and enhanced HDL functionality to inhibit oxidation and glycation of LDL and HDL, as well as lowering blood pressure in a dose-dependent manner. Independent corroboration of blood pressure effects from non-Cuban research groups remains limited.

5.3 Platelet Aggregation and Peripheral Vascular Disease

Policosanol has been studied in platelet aggregation and intermittent claudication, but data are insufficient to support this use. Some clinical research shows that taking policosanol 10–50 mg daily for 7–15 days can inhibit platelet aggregation in healthy patients. The potential benefit for intermittent claudication is thought to be due to policosanol's ability to prevent platelets in the blood from sticking together and its potential anti-inflammatory activity; however, human studies have not shown it to consistently improve symptoms in people with intermittent claudication.

There is a multitude of research originating from Cuba showing benefits on platelet aggregation, physical performance secondary to blood flow (intermittent claudication or heart disease), and adverse effects reduction related to heart disease. However, counter-evidence shows that the only study conducted outside Cuba on blood clotting (Croatia) noted no effects, and an Australian study noted no interactions with warfarin efficacy (a blood thinner).

Evidence strength (platelet aggregation / intermittent claudication): Preliminary, primarily from a single Cuban research group. Independent confirmation is lacking. Evidence is insufficient to support a definitive therapeutic claim.

5.4 Neurological Health: Parkinson's Disease and Neuroprotection

Policosanol has been shown to prevent and alleviate symptoms associated with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Recent studies have demonstrated the role of policosanols from insect waxes as effective products on Caenorhabditis elegans models of both Parkinson's and Alzheimer's diseases. Preclinical evidence in rodent models showed that octacosanol (the dominant policosanol component) exerted protective effects in 6-hydroxydopamine-induced Parkinsonian rats.

Neuroprotective benefit from policosanol may occur through its antioxidant activity, but clinical evidence is lacking.

Evidence strength (neuroprotection): Preclinical only (invertebrate models and rodent models). No human clinical trials on nonacosanol or policosanol for any neurodegenerative condition have been published. Evidence is entirely preliminary and not translatable to clinical recommendations.

5.5 Cancer Research

Policosanols have been investigated in vitro against human gastric SNU-16 cancer cells and in an in vivo xenograft mouse model. Policosanol (PC) extracted from Cuban sugar cane wax is described as a healthy functional food ingredient. Its various physiological activities, such as antioxidant, anti-inflammatory, and anticancer activities, have been reported recently. Nevertheless, the therapeutic efficacy of PC in gastric xenograft models was investigated. Researchers aimed to investigate the anticancer effect of PC on human GC SNU-16 cells and a xenograft mouse model.

Evidence strength (cancer): In vitro and animal data only. No human clinical evidence exists. This area of research should be considered entirely exploratory.

5.6 Gut Microbiota and Metabolic Effects

An animal study using a high-fat diet C57BL/6 mouse model found that policosanol supplementation significantly reduced serum triglycerides and total cholesterol, as well as the weight of brown adipose tissue (BAT), without affecting body weight in HFD-fed mice. Combined 16S rRNA gene sequencing and untargeted metabolomic analysis demonstrated that policosanol had regulatory effects on gut microbiota and serum metabolism in mice. These findings are preliminary and have not yet been replicated in human clinical trials.

5.7 Ischemic Stroke Recovery

Policosanol (20 mg/day) was tested in combination with aspirin (125 mg/day) for six months in two RCTs including a total of 142 hypertensive patients who experienced a non-cardioembolic ischemic stroke in the prior 30 days of moderate severity based on a score of 2 to 4 on the modified Rankin scale (mRS). A greater proportion of policosanol-treated patients achieved mRS values ≤ 1 (80.3%), relative to those in comparator groups.

Evidence strength (stroke recovery): Two small Cuban-conducted RCTs (total n=142). Results have not been independently replicated. Evidence is preliminary.

6. Body Systems and Health Areas

Based on the published literature on policosanol mixtures that include nonacosanol, the following body systems have been studied:

Cardiovascular system: A wide array of preclinical and clinical studies establishes an impactful role of policosanol in reducing total cholesterol (TC), triglycerides (TGs), and LDL-cholesterol. Platelet aggregation inhibition and blood pressure have also been studied.
Hepatic/metabolic system: Dietary treatment with policosanol resulted in a significant decrease of blood cholesterol, blood glucose, triglyceride, and LDL-cholesterol levels, and HMG-CoA reductase activity in the liver, indicating that policosanol decreases blood cholesterol levels by suppressing cholesterol biosynthesis via decrease of HMG-CoA activity.
Central nervous system: Preclinical evidence for anti-Parkinsonian and neuroprotective effects through antioxidant mechanisms and modulation of JNK phosphorylation.
Immune/inflammatory system: In vitro assays indicated an inhibition of intracellular ROS production and a reduction of NF-κB activation.
Peripheral vascular system: Studies on intermittent claudication, platelet aggregation, and blood flow; results inconsistent across independent research groups.
Hematological system: Antiplatelet effects studied; potential interactions with anticoagulant therapy noted.

7. Dosage Forms and Reported Dosages

7.1 Available Forms

Policosanol is available in the form of OTC supplements. It has not been approved for any indication. Policosanol is a dietary supplement derived from a mixture of waxy substances, primarily obtained from sugarcane. Commercial forms include tablets and capsules. Products marketed as policosanol in the United States are often derived from beeswax or wheat germ, differing in composition from the sugarcane version and lacking robust research support.

Policosanol, a mixture of long-chain alcohols found in animal and plant waxes, has several biological effects; however, it has a bioavailability of less than 10%. Therefore, there is a need to improve its bioavailability, and one of the ways of doing this is by nanoemulsion formulation.

7.2 Dosages Used in Published Clinical Research

Because nonacosanol is present as a minor component (1.0–20.0 mg/g) of policosanol, the dosages below refer to total policosanol mixture amounts as reported in the peer-reviewed clinical literature:

5 mg/day: Used in a double-blind, placebo-controlled trial of 56 hypercholesterolemic patients for 8 weeks (after 6 weeks dietary lead-in).
5–20 mg/day (range): Policosanol is a well-defined mixture of higher aliphatic primary alcohols isolated from sugar cane wax with cholesterol-lowering effects proven for a dose range from 5–20 mg/day in patients with type II hypercholesterolemia and dyslipidemia associated with non-insulin-dependent diabetes mellitus (in Cuban trials).
10–80 mg/day: Later trials published from 2006 to 2009 in the United States, Italy, Germany, Netherlands, Canada, and South Africa used dosages of 10 to 80 mg daily over 4 to 12 weeks and found no effect on blood lipid profiles.
20 mg/day: The Raydel® policosanol tablet (two tablets of 10 mg, total 20 mg per day) was used in a 12-week randomized, double-blind trial in healthy Japanese subjects.
40 mg/day (adjunctive use): Adjunctive use of 40 mg/day for 30 days has been used with antiplatelet regimens after percutaneous stent implantation.
10–50 mg/day for 7–15 days: Used in research on platelet aggregation inhibition in healthy patients.
20 mg/day + aspirin 125 mg/day for 6 months: Tested in two RCTs including 142 hypertensive patients who experienced non-cardioembolic ischemic stroke.
Typical initiation/titration: Policosanol is typically initiated at 5 mg/day and titrated up to 20 mg/day for hypercholesterolemia.

The amount of each of these alcohols can vary from product to product. Each of these alcohols may have different effects on the body. These effects may change depending on how much of each alcohol is found in the product being taken.

8. Safety Considerations and Drug Interactions

8.1 General Tolerability

At dosages of up to 20 mg per day, policosanol is safe and well tolerated, as studies of more than 3 years of therapy indicate. Policosanol is well-tolerated with an adverse event profile comparable to placebo. Long-term safety has not been established.

In the Cuban double-blind trial of 56 patients at 5 mg/day: no significant differences in clinical and biochemical safety indicators were seen in the treated patients compared with those receiving placebo. There were no adverse effects attributable to treatment, and no patient was withdrawn from the trial. These data indicate that policosanol therapy is very well tolerated.

In the comparative 20 vs. 40 mg/day Cuban study: no unexpected adverse effects were observed and there were no significant between-group differences regarding safety indicator values or reported adverse effects.

8.2 Contraindications and Special Populations

Contraindications have not been identified. Information regarding safety and efficacy in pregnancy and lactation is lacking. Studies in rats and mice demonstrated no adverse effects on fertility, reproduction, teratogenesis, or development at doses equivalent to 1,500 times the normal human dose of 20 mg/day.

8.3 Interaction with Anticoagulant and Antiplatelet Drugs

Because of policosanol's potential effects on platelet aggregation, caution is warranted if it is used concurrently with anticoagulants (e.g., warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel, prasugrel). However, a study in 11 healthy men receiving warfarin 25 mg before and after treatment with policosanol 10 mg twice daily for 2 weeks found no effect of policosanol on the pharmacokinetics of (S)- or (R)-warfarin. Policosanol also did not alter the response to warfarin on platelet aggregation.

In animal models: policosanol did not change the bleeding time; meanwhile warfarin alone and the combination policosanol + warfarin induced a moderate, but significant, prolongation of the bleeding time. The addition of policosanol to warfarin therapy did not enhance the prolongation of the bleeding time induced by warfarin alone. When the combination was used instead of either drug alone, no significant benefits were observed on the reduction of thrombus weight.

One study on policosanol in stent implantation found that taking policosanol 40 mg plus clopidogrel and aspirin daily for 30 days modestly reduced the risk for minor bleeding events when compared with taking clopidogrel and aspirin alone.

8.4 Interaction with Beta-Adrenoceptor Antagonists

In one randomized controlled trial, two of three policosanol-treated participants (2 mg/day for 14 months) who concomitantly received beta-adrenoceptor antagonists showed an increase in triglycerides and no change in total cholesterol. Beta-adrenoceptor antagonists are known to increase triglycerides and VLDL cholesterol, and to decrease HDL cholesterol. Suprapharmacological doses of policosanol have been shown to significantly increase propranolol-induced hypotension in spontaneously hypertensive rats, while having no effect on blood pressure when concomitantly administered with nifedipine.

8.5 Interaction with Statins

The interactions between policosanol and medicines are not fully understood. Given that policosanol's postulated mechanism involves the AMPK/HMG-CoA reductase axis — the same enzymatic target as statin drugs — the potential for additive cholesterol-lowering effects or altered statin pharmacodynamics has been proposed, but has not been definitively characterized in human studies.

8.6 Product Quality and Compositional Variability

Havana-based Dalmer Laboratories' Cuban policosanol product is backed by science, but the company did not register the trademark 'policosanol,' so any entity can associate this name with products or ingredients containing long-chain alcohols. Some companies have introduced imitations and falsely claimed for them the scientific efficacy of the Cuban original.

The amount and stability of policosanols affect the health benefits; however, while many products claim to contain policosanols, data on the amounts and stability, including in dietary supplements and rice bran oil, are limited. This compositional variability is especially relevant to nonacosanol, which as a minor component (1.0–20.0 mg/g in standardized Cuban policosanol) may be present at very different concentrations — or absent entirely — in non-Cuban policosanol preparations.

9. Research Limitations and Evidence Gaps

The evidence base for nonacosanol faces several fundamental limitations that must be acknowledged:

No independent human studies on nonacosanol: No published randomized controlled trial, observational study, or pharmacokinetic investigation has examined 1-nonacosanol as an isolated compound in human subjects. All evidence is derived from research on policosanol mixtures.
Minor constituent status: At 1.0–20.0 mg/g of the total mixture, nonacosanol represents only a small fraction of Cuban policosanol. Its independent pharmacological contribution cannot be separated from the collective activity of the eight-component mixture.
Publication bias in the policosanol literature: Virtually all of the published medical literature on policosanol has been authored by research groups in Cuba. This possible publication bias shows in studies on LDL oxidation, where a Cuban study reported benefit while a study conducted in Montreal, Canada reported no such effect.
Source-dependent composition: The quality of this natural product depends on its source and composition. Nonacosanol content may differ substantially between sugarcane, rice bran, beeswax, and wheat germ preparations.
Bioavailability challenges: The less-than-10% oral bioavailability of policosanol as a whole, and the uncertainty about individual alcohol absorption kinetics, means that effective tissue concentrations of nonacosanol after typical dietary supplementation are unknown.
Dose-mechanism gap: Although policosanol increases the phosphorylation of HMG-CoA reductase in mouse liver after intragastric administration, the ability of therapeutically recommended doses of policosanol to decrease blood cholesterol levels by this pathway remains in doubt, given that the preclinical doses are considerably higher than those used in clinical studies.
Regulatory status: The FDA has not reviewed policosanol for safety and effectiveness. No regulatory body has approved policosanol or any of its individual alcohols as a treatment for any condition.

References

Health Conditions

Health conditions that Nonacosanol may help support.

No conditions available.

Body Systems

Body systems that Nonacosanol may help support.

No body systems available.